【中泰医药|公司点评】昆药集团：Q4业绩超预期，看好25年拐点向上

锵锵药市三人行02-12

事件：公司发布2024年业绩快报，报告期内实现营业收入84.01亿元，追溯调整后同比下降0.34%；实现归母净利润6.48亿元，追溯调整后同比增长19.86%；实现扣非净利润4.36亿元，同比增长30.14%。■ Q4业绩超预期，调整期已过、经营质量充分夯实。根据业绩快报，单四季度公司实现归母净利润2.61亿元、扣非净利润1.47亿元，均实现大幅提升。公司业绩超预期的主要原因为：1）23Q4历史...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2510195328?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-12 16:58","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2510195328","market":"sh","top_or_hot":-1,"title":"【中泰医药|公司点评】昆药集团：Q4业绩超预期，看好25年拐点向上","media":"锵锵药市三人行","content":"<div>\n<p>事件：公司发布2024年业绩快报，报告期内实现营业收入84.01亿元，追溯调整后同比下降0.34%；实现归母净利润6.48亿元，追溯调整后同比增长19.86%；实现扣非净利润4.36亿元，同比增长30.14%。■ Q4业绩超预期，调整期已过、经营质量充分夯实。根据业绩快报，单四季度公司实现归母净利润2.61亿元、扣非净利润1.47亿元，均实现大幅提升。公司业绩超预期的主要原因为：1）23Q4历史...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021216571198829a12&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【中泰医药|公司点评】昆药集团：Q4业绩超预期，看好25年拐点向上</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【中泰医药|公司点评】昆药集团：Q4业绩超预期，看好25年拐点向上\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-12 16:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021216571198829a12&s=b><strong>锵锵药市三人行</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>事件：公司发布2024年业绩快报，报告期内实现营业收入84.01亿元，追溯调整后同比下降0.34%；实现归母净利润6.48亿元，追溯调整后同比增长19.86%；实现扣非净利润4.36亿元，同比增长30.14%。■ Q4业绩超预期，调整期已过、经营质量充分夯实。根据业绩快报，单四季度公司实现归母净利润2.61亿元、扣非净利润1.47亿元，均实现大幅提升。公司业绩超预期的主要原因为：1）23Q4历史...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021216571198829a12&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021216571198829a12&s=b","article_id":"2510195328","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021216571198829a12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2510195328","pubTimestamp":1739350693,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"■ Q4业绩超预期，调整期已过、经营质量充分夯实。■工业板块加速追赶5年规划目标，2025年经营拐点在即。考虑到公司已平稳度过整合调整期，借力华润构建昆药商道后，公司品牌力和营销力得到提升，随融合深入盈利能力有望持续提升，维持“买入”评级。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","600080":"金花股份","600085":"同仁堂","600129":"太极集团","600222":"太龙药业","600252":"中恒集团","600285":"羚锐制药","600329":"达仁堂","600332":"白云山","600351":"亚宝药业","600422":"昆药集团","600436":"片仔癀","600479":"千金药业","600518":"康美药业","600535":"天士力","600557":"康缘药业","600566":"济川药业","600572":"康恩贝","600594":"益佰制药","600671":"ST目药","600750":"江中药业","600771":"广誉远","600976":"健民集团","600993":"马应龙","603139":"康惠制药","603439":"贵州三力","603567":"珍宝岛","603858":"步长制药","603896":"寿仙谷","603963":"*ST大药","603998":"方盛制药","605199":"葫芦娃","BK0239":"医药制造","BK0183":"MSCI概念","BK0012":"证金概念","BK0196":"行业龙头","BK0097":"医药电商","BK0060":"抗癌","BK0028":"国家队","BK0113":"养老产业","BK0086":"举牌","LU1688375341.USD":"贝莱德中国灵活股票基金","BK0188":"融资融券"},"translate_title":"[Zhongtai Pharmaceutical Company Comments] Kunyao Group: Q4 performance exceeded expectations, optimistic about the upward inflection point in 25 years","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"600080":0.9,"600085":0.9,"600129":0.9,"600222":0.9,"600252":0.9,"600285":0.9,"600329":0.9,"600332":0.9,"600351":0.9,"600422":1,"600436":0.9,"600479":0.9,"600518":0.9,"600535":0.9,"600557":0.9,"600566":0.9,"600572":0.9,"600594":0.9,"600671":0.9,"600750":0.9,"600771":0.9,"600976":0.9,"600993":0.9,"603139":0.9,"603439":0.9,"603567":0.9,"603858":0.9,"603896":0.9,"603963":0.9,"603998":0.9,"605199":0.9},"content_text":"事件：公司发布2024年业绩快报，报告期内实现营业收入84.01亿元，追溯调整后同比下降0.34%；实现归母净利润6.48亿元，追溯调整后同比增长19.86%；实现扣非净利润4.36亿元，同比增长30.14%。■ Q4业绩超预期，调整期已过、经营质量充分夯实。根据业绩快报，单四季度公司实现归母净利润2.61亿元、扣非净利润1.47亿元，均实现大幅提升。公司业绩超预期的主要原因为：1）23Q4历史遗留问题充分出清，计提资产减值及信用减值合计约6400万，导致23Q4业绩基数较低；2）2024年12月公司完成华润圣火51%股权的收购，根据此前收购公告，2023年华润圣火实现净利润2亿元，我们预计24Q4华润圣火的并表贡献约1亿左右；3）公司与华润三九实现深度融合后，持续强化在慢病管理尤其是老龄健康领域、三七系列产品及“昆中药1381”“777”的品牌优势，不断提升公司业务规模，增厚公司业绩。■工业板块加速追赶5年规划目标，2025年经营拐点在即。公司控股股东变更为华润三九2年多，现已平稳度过融合期，人事、组织架构调整完毕，渠道变革顺利推进、即将释放改革成效。展望2025年，1）针剂业务在医保试点到期及集采影响下2024年受损明显，随着集采续约平稳落地，预计25年将会迎来恢复性增长；2）昆药商道加速构建，品牌和渠道赋能下，有望带动昆中药1381和血塞通777两大事业部发力，带动业绩拐点向上。■盈利预测和投资建议：根据业绩快报我们对盈利预测略做调整，预计2024-2026年公司实现营业收入84.01、91.69、100.10亿元（预测前值为84.62、92.16、100.58亿元），同比增长9%、9%、9%，实现归母净利润6.48、7.42、9.05亿元（预测前值为6.07、7.20、8.61亿元），同比增长46%、14%、22%。考虑到公司已平稳度过整合调整期，借力华润构建昆药商道后，公司品牌力和营销力得到提升，随融合深入盈利能力有望持续提升，维持“买入”评级。■风险提示：中药行业政策风险，产品推广不达预期风险，原材料价格波动风险，研究报告使用的公开资料可能存在信息滞后或更新不及时的风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2510195328"}